The epidemiology of fecal carriage of nontyphoidal Salmonella among healthy children and adults in three sites in Kenya.
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
11
04
2023
accepted:
10
10
2023
revised:
07
11
2023
medline:
8
11
2023
pubmed:
26
10
2023
entrez:
26
10
2023
Statut:
epublish
Résumé
Despite the importance of non-Typhoidal Salmonella (NTS) disease in Africa, epidemiologic data on carriage and transmission are few. These data are important to understand the transmission of NTS in Africa and to design control strategies. To estimate the prevalence of stool carriage of NTS in Kenya, we conducted a cross-sectional study in Kilifi, Nairobi, and Siaya, sites with a low, moderate and high incidence of invasive NTS disease, respectively. At each site, we randomly selected 100 participants in each age-group of 0-11 months, 12-59 months, 5-14 years, 15-54 years and ≥55 years. We collected stool, venous blood (for hemoglobin and malaria rapid tests), anthropometric measurements, and administered a questionnaire on Water Access Sanitation and Hygiene (WASH) practices. Stool samples were cultured on selective agar for Salmonella; suspect isolates underwent serotyping and antimicrobial susceptibility testing. Overall, 53 (3.5%) isolates of NTS were cultured from 1497 samples. Age-adjusted prevalence was 13.1% (95%CI 8.8-17.4) in Kilifi, 0.4% (95%CI 0-1.3) in Nairobi, and 0.9% (95%CI 0-2.0) in Siaya. Prevalence was highest among those aged 15-54 years (6.2%). Of 53 isolates; 5 were S. Enteritidis, 1 was S. Typhimurium. No S. Typhi was isolated. None of the risk factors were associated with carriage of NTS. All isolates were susceptible to all antibiotics tested, including ampicillin, chloramphenicol, ciprofloxacin and co-trimoxazole. Prevalence of fecal carriage was high in Kilifi, an area of low incidence of invasive NTS disease and was low in areas of higher incidence in Nairobi and Siaya. The age-prevalence, risk factors, geographical and serotype distribution of NTS in carriage differs from invasive disease.
Sections du résumé
BACKGROUND
BACKGROUND
Despite the importance of non-Typhoidal Salmonella (NTS) disease in Africa, epidemiologic data on carriage and transmission are few. These data are important to understand the transmission of NTS in Africa and to design control strategies.
METHOD
METHODS
To estimate the prevalence of stool carriage of NTS in Kenya, we conducted a cross-sectional study in Kilifi, Nairobi, and Siaya, sites with a low, moderate and high incidence of invasive NTS disease, respectively. At each site, we randomly selected 100 participants in each age-group of 0-11 months, 12-59 months, 5-14 years, 15-54 years and ≥55 years. We collected stool, venous blood (for hemoglobin and malaria rapid tests), anthropometric measurements, and administered a questionnaire on Water Access Sanitation and Hygiene (WASH) practices. Stool samples were cultured on selective agar for Salmonella; suspect isolates underwent serotyping and antimicrobial susceptibility testing.
RESULT
RESULTS
Overall, 53 (3.5%) isolates of NTS were cultured from 1497 samples. Age-adjusted prevalence was 13.1% (95%CI 8.8-17.4) in Kilifi, 0.4% (95%CI 0-1.3) in Nairobi, and 0.9% (95%CI 0-2.0) in Siaya. Prevalence was highest among those aged 15-54 years (6.2%). Of 53 isolates; 5 were S. Enteritidis, 1 was S. Typhimurium. No S. Typhi was isolated. None of the risk factors were associated with carriage of NTS. All isolates were susceptible to all antibiotics tested, including ampicillin, chloramphenicol, ciprofloxacin and co-trimoxazole.
CONCLUSION
CONCLUSIONS
Prevalence of fecal carriage was high in Kilifi, an area of low incidence of invasive NTS disease and was low in areas of higher incidence in Nairobi and Siaya. The age-prevalence, risk factors, geographical and serotype distribution of NTS in carriage differs from invasive disease.
Identifiants
pubmed: 37883602
doi: 10.1371/journal.pntd.0011716
pii: PNTD-D-23-00433
pmc: PMC10629669
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0011716Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : EPA
ID : EP-C-15-003
Pays : United States
Informations de copyright
Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Références
J Infect Dis. 2008 Jul 1;198(1):109-14
pubmed: 18462137
Rev Infect Dis. 1984 May-Jun;6(3):345-56
pubmed: 6377442
PLoS Negl Trop Dis. 2019 Oct 14;13(10):e0007782
pubmed: 31609964
Nat Rev Immunol. 2015 Jul;15(7):452-63
pubmed: 26109132
Lancet. 2012 Jun 30;379(9835):2489-2499
pubmed: 22587967
BMC Infect Dis. 2020 Jun 17;20(1):422
pubmed: 32552753
PLoS Negl Trop Dis. 2015 Jan 08;9(1):e3394
pubmed: 25569606
Infect Genet Evol. 2020 Nov;85:104534
pubmed: 32920195
Lancet Infect Dis. 2019 Dec;19(12):1312-1324
pubmed: 31562022
Clin Infect Dis. 2015 Nov 1;61 Suppl 4:S302-9
pubmed: 26449945
Int J Epidemiol. 2012 Aug;41(4):977-87
pubmed: 22933646
Am J Epidemiol. 1980 Nov;112(5):707-23
pubmed: 6969024
PLoS Negl Trop Dis. 2020 Feb 21;14(2):e0007875
pubmed: 32084128
Emerg Infect Dis. 2015 Jun;21(6):
pubmed: 25860298
Genome Res. 2009 Dec;19(12):2279-87
pubmed: 19901036
Clin Infect Dis. 2014 Mar;58(5):638-47
pubmed: 24336909
Clin Infect Dis. 2001 Jan 15;32(2):263-9
pubmed: 11170916
Int J Epidemiol. 2012 Jun;41(3):650-7
pubmed: 22544844
Vet Res. 2011 Feb 14;42:34
pubmed: 21324103
ScientificWorldJournal. 2015;2015:520179
pubmed: 25664339
Epidemiol Infect. 2020 May 26;148:e144
pubmed: 32450932
PLoS Negl Trop Dis. 2020 Aug 3;14(8):e0008440
pubmed: 32745137
Clin Infect Dis. 2016 Mar 15;62 Suppl 1:S50-5
pubmed: 26933022
Clin Infect Dis. 2015 Nov 1;61 Suppl 4:S290-301
pubmed: 26449944
N Engl J Med. 2005 Jan 6;352(1):39-47
pubmed: 15635111
Clin Microbiol Infect. 2011 Sep;17(9):1421-5
pubmed: 21175956
Nat Genet. 2016 Oct;48(10):1211-1217
pubmed: 27548315
Front Microbiol. 2019 Jun 26;10:1368
pubmed: 31316476
Rev Infect Dis. 1982 Nov-Dec;4(6):1096-106
pubmed: 6760337
Clin Infect Dis. 2010 Mar 15;50(6):882-9
pubmed: 20158401
Lancet Infect Dis. 2010 Jun;10(6):417-32
pubmed: 20510282
Clin Infect Dis. 2021 Aug 16;73(4):631-641
pubmed: 33493332
Pediatr Infect Dis J. 2010 Oct;29(10):945-9
pubmed: 20418799
PLoS Negl Trop Dis. 2011;5(5):e1148
pubmed: 21655353
J Med Microbiol. 2006 May;55(Pt 5):585-591
pubmed: 16585646
Euro Surveill. 2010 Jun 03;15(22):19581
pubmed: 20546689
Trans R Soc Trop Med Hyg. 2017 Sep 1;111(9):418-424
pubmed: 29342283
PLoS Pathog. 2012;8(6):e1002776
pubmed: 22737074
Vaccine. 2009 Sep 4;27(40):5513-8
pubmed: 19615960
PLoS One. 2012;7(2):e31237
pubmed: 22363591
PLoS One. 2011 Jan 18;6(1):e16085
pubmed: 21267459